USA flag logo/image

An Official Website of the United States Government

Novel Topical Treatment for Disorders of Keratinization

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75973
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AR052213
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Novel Topical Treatment for Disorders of Keratinization
Agency: HHS
Contract: 1R43AR052213-01
Award Amount: $128,334.00
 

Abstract:

DESCRIPTION (provided by applicant): Disorders of keratinization are a heterogeneous group of diseases characterized by dry and scaly skin that demonstrate changes in the biophysical properties of the stratum corneum, especially with respect to the water permeability barrier. These diseases, also known as disorders of cornification, include various forms of ichthyosis, palmoplantar keratoderma, and follicular keratoses such as Darier's disease and keratosis pilaris. Keratosis pilaris is prevalent in 40% of the population, and as high as 80% of adolescent women. Current treatment options include the use of emollients and moisturizers, and keratolytic agents including salicylic acid, urea, or alpha hydroxy acids. The goal of this project is to evaluate a patented polymer-based coating technology as a novel topical treatment for disorders of keratinization. In order to demonstrate feasibility and effectiveness of the coatings, the following Specific Aims will be pursued: Aim 1. Formulate Coatings for the Treatment of Diseases of Keratinization. The coating formulation will be optimized to provide coatings suitable for use in the treatment of disorders of keratinization. Keratolytic agents will be incorporated into coatings to investigate compatibility with the formulation. Aim 2. Demonstrate Efficacy of Coatings in a Human Clinical Trial. This assay will demonstrate the effectiveness of skin coatings in treating a disorder of keratinization. A double-blind, right/left comparison will be made between the skin coating and the skin coating containing a keratolytic agent.

Principal Investigator:

Bakul M. Bhatt
2103080636
BHATT@BIODEVCORP.COM

Business Contact:

Gregg Siegel
2103080636
GSIEGEL@BIODEVCORP.COM
Small Business Information at Submission:

Biomedical Development Corporation
Biomedical Development Corp 500 Sandau, Ste 200 San Antonio, TX 78216

EIN/Tax ID: 742330067
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No